Paloma Partners Management Co raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 2,512.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,374 shares of the medical equipment provider’s stock after buying an additional 136,924 shares during the period. Paloma Partners Management Co’s holdings in Hologic were worth $5,852,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Candriam Luxembourg S.C.A. bought a new position in shares of Hologic during the fourth quarter valued at $504,000. MML Investors Services LLC raised its stake in shares of Hologic by 6.8% during the fourth quarter. MML Investors Services LLC now owns 6,441 shares of the medical equipment provider’s stock valued at $265,000 after acquiring an additional 412 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Hologic by 25.3% during the fourth quarter. Bank of America Corp DE now owns 1,108,059 shares of the medical equipment provider’s stock valued at $45,541,000 after acquiring an additional 223,725 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in shares of Hologic by 90.1% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,194 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 566 shares during the last quarter. Finally, Menta Capital LLC bought a new position in shares of Hologic during the fourth quarter valued at $321,000. Hedge funds and other institutional investors own 85.85% of the company’s stock.

In other Hologic news, insider Benjamin Jordan Cohn sold 6,830 shares of Hologic stock in a transaction on Monday, March 11th. The shares were sold at an average price of $46.70, for a total value of $318,961.00. Following the completion of the sale, the insider now directly owns 22,002 shares of the company’s stock, valued at $1,027,493.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Peter J. Valenti III sold 4,242 shares of Hologic stock in a transaction on Friday, March 1st. The shares were sold at an average price of $47.38, for a total transaction of $200,985.96. The disclosure for this sale can be found here. 0.90% of the stock is owned by company insiders.

Shares of NASDAQ HOLX opened at $47.25 on Tuesday. Hologic, Inc. has a twelve month low of $35.10 and a twelve month high of $48.11. The firm has a market cap of $13.74 billion, a P/E ratio of 21.19, a PEG ratio of 2.23 and a beta of 0.75. The company has a quick ratio of 0.91, a current ratio of 1.30 and a debt-to-equity ratio of 1.18.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.01. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The business had revenue of $830.70 million during the quarter, compared to the consensus estimate of $823.22 million. During the same quarter last year, the firm earned $0.55 earnings per share. Hologic’s quarterly revenue was up 5.0% on a year-over-year basis. On average, research analysts predict that Hologic, Inc. will post 2.41 EPS for the current fiscal year.

Several equities analysts have recently issued reports on the stock. BidaskClub raised shares of Hologic from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 21st. Piper Jaffray Companies raised their price target on shares of Hologic to $49.00 and gave the company an “overweight” rating in a research note on Thursday, January 31st. BTIG Research reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a research note on Thursday, January 31st. Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Thursday, February 21st. Finally, Morgan Stanley downgraded shares of Hologic from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $44.00 to $39.00 in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $44.52.

COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Shares Bought by Paloma Partners Management Co” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2019/03/19/hologic-inc-holx-shares-bought-by-paloma-partners-management-co.html.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.